Magee Womens Hospital, Pittsburgh, PA
Shannon Puhalla , Sharon Wilks , Adam Brufsky , Joyce O'Shaughnessy , Lee Steven Schwartzberg , Erhan Berrak , James Song , David Cox , Linda T. Vahdat
Background: Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor in the halichondrin class of antineoplastic drugs, is indicated for women with MBC who previously received ≥2 chemotherapy regimens in the metastatic setting. Primary data from a phase 2 trial on first-line combination eribulin + trastuzumab (TRAS) in HER2+ patients (pts) showed a 71% objective response rate (ORR) and tolerability consistent with the known profile of these agents. Here we present prespecified endpoint data for this study by prior TRAS use. Methods: Pts with HER2+ MBC who had not received prior chemotherapy for MBC received eribulin mesylate 1.4 mg/m2IV on days 1 and 8 of each 21-day cycle and initial TRAS (8 mg/kg IV/day 1), followed by 6 mg/kg/day 1 of each subsequent cycle. Response, progression-free survival (PFS), and tolerability were assessed in patients who had and had not received prior TRAS treatment. Results: The 52 pts (median age, 59.5 years) received combination eribulin + TRAS, for a median treatment duration of ~30 weeks; 40% (n=21) were previously treated with TRAS in the neo-adjuvant / adjuvant setting. There was median of 23 months since completion of adjuvant treatment prior to retreatment with eribulin + TRAS for first-line MBC.Efficacy, assessed by ORR, clinical benefit rate (CBR), PFS, and duration of response (DOR), was largely consistent in pts who received prior TRAS relative to pts who had not received prior TRAS (see table). Overall, Grade (G) 3-5 adverse events (AEs), treatment-related AEs (TRAEs), and discontinuations (d/c) were similar between groups (Table). Conclusions: In this phase 2 single-arm trial in pts with HER2+ MBC, eribulin + TRAS demonstrated activity and was well tolerated as first-line treatment, irrespective of prior (neo) adjuvant TRAS treatment. Clinical trial information: NCT01269346.
HER2+ pts (N=52) |
||
---|---|---|
w/ prior TRAS | w/o prior TRAS | |
n (%) | 21 (40) | 31 (60) |
ORR, n (%) | 13 (62) | 24 (77) |
CBR, n (%) | 17 (81) | 27 (87) |
PFS, m (median) | 11.5 | 12.2 |
DOR, m (median) | 9.5 | 11.8 |
AEs, G3-4, n (%) | 16 (76) | 21 (68) |
AEs, G5, n (%) | 0 (0) | 1 (2) |
TRAE, n (%) | 21 (100) | 31 (100) |
AEs leading to d/c, n (%) | 5 (24) | 6 (19) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
First Author: Nicholas Patrick McAndrew
2022 ASCO Annual Meeting
First Author: Ian E. Krop
2014 Breast Cancer Symposium
First Author: Stefan Gluck
2014 ASCO Annual Meeting
First Author: Stefan Gluck